Disease modifying therapy in the treatment of tumefactive multiple sclerosis: A retrospective cohort study

被引：0

作者：

Galetta, Kristin ^{[1
,2
,4
]}

Ham, Andrew Siyoon ^{[3
]}

Vishnevetsky, Anastasia ^{[3
]}

Bhattacharyya, Shamik ^{[2
]}

Mateen, Farrah J. ^{[3
]}

机构：

[1] Stanford Univ, Dept Neurol, Palo Alto, CA USA

[2] Brigham & Womens Hosp, Dept Neurol, Boston, MA USA

[3] Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA

[4] Stanford Univ, Dept Neurol, 203 Quarry Rd, Palo Alto, CA 94305 USA

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2024年 / 388卷

关键词：

Disease modifying therapy; Tumefactive multiple sclerosis; Demyelinating disease; Multiple sclerosis; OCRELIZUMAB; DIAGNOSIS;

D O I：

10.1016/j.jneuroim.2024.578299

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Tumefactive multiple sclerosis (TMS) is characterized by large demyelinating brain lesions. This was a retrospective cohort study of 67 patients with TMS between January 2015-2023, examining different disease modifying therapy impact on expanded disability scale score change at follow-up. Median age was 36 with a female predominance. Mean EDSS was 3.3 +/- 2.3 at TMS onset, 2.1 +/- 1.9 at year one, and 2.1 +/- 1.9 at last follow-up. A multilinear regression model found higher presentation EDSS and post-diagnosis non-B-cell high efficacy therapies were each independently associated with higher EDSS at last follow up. Further research is needed to determine the value of B-cell therapy in TMS.

引用

页数：7

共 27 条

[1] Tumefactive demyelinating lesions: A comprehensive review
Algahtani, Hussein
Shirah, Bader
Alassiri, Ali
[J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 14 : 72 - 79
[2] Alvarez Enrique, 2015, Mult Scler J Exp Transl Clin, V1, p2055217315623800, DOI 10.1177/2055217315623800
[3] Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis
Barkhof, F
Filippi, M
Miller, DH
Scheltens, P
Campi, A
Polman, CH
Comi, G
Ader, HJ
Losseff, N
Valk, J
[J]. BRAIN, 1997, 120 : 2059 - 2069
[4] Bazzurri V, 2022, Neuroimmunol. Rep., V2, DOI [10.1016/j.nerep.2022.100122, DOI 10.1016/J.NEREP.2022.100122]
[5] The elimination of circulating Epstein-Barr virus infected B cells underlies anti-CD20 monoclonal antibody activity in multiple sclerosis: A hypothesis
Berger, Joseph R.
Kakara, Mihir
[J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 59
[6] Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments
Brod, Staley A.
Lindsey, J. William
Nelson, Flavia
[J]. MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2019, 5 (02)
[7] Clinical instrument to retrospectively capture levels of EDSS
Ciotti, John Robert
Sanders, Noah
Salter, Amber
Berger, Joseph R.
Cross, Anne Haney
Chahin, Salim
[J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 39
[8] Dagher AP, 1996, NEURORADIOLOGY, V38, P560
[9] Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study
Di Gregorio, Maria
Torri Clerici, Valentina Liliana Adriana
Fenu, Giuseppe
Gaetani, Lorenzo
Gallo, Antonio
Cavalla, Paola
Ragonese, Paolo
Annovazzi, Pietro
Gajofatto, Alberto
Prosperini, Luca
Landi, Doriana
Nicoletti, Carolina Gabri
Di Carmine, Caterina
Totaro, Rocco
Nociti, Viviana
De Fino, Chiara
Ferraro, Diana
Tomassini, Valentina
Tortorella, Carla
Righini, Isabella
Amato, Maria Pia
Manni, Alessia
Paolicelli, Damiano
Iaffaldano, Pietro
Lanzillo, Roberta
Moccia, Marcello
Buttari, Fabio
Fantozzi, Roberta
Cerqua, Raffaella
Zagaglia, Sara
Farina, Deborah
De Luca, Giovanna
Buscarinu, Maria Chiara
Pinardi, Federica
Cocco, Eleonora
Gasperini, Claudio
Solaro, Claudio Marcello
Di Filippo, Massimiliano
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (04) : 1299 - 1307
[10] Cyclophosphamide in treatment of tumefactive multiple sclerosis
Fereidan-Esfahani, Mahboobeh
Tobin, W. Oliver
[J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 47

← 1 2 3 →